Innovative Cellular Therapeutics

Innovative Cellular Therapeutics

Pharmaceuticals, 1405 Research BLVD, Rockville, Maryland, 20850, United States, 51-200 Employees

ictbio.com

  • LinkedIn

Who is INNOVATIVE CELLULAR THERAPEUTICS

Innovative Cellular Therapeutics (ICT) is a clinical-stage, VC-backed cell therapy company based in Rockville, MD. ICT has established a broad portfolio of CAR-T products to treat cancer ...

Read More

map
  • 1405 Research BLVD, Rockville, Maryland, 20850, United States Headquarters: 1405 Research BLVD, Rockville, Maryland, 20850, United States
  • 2009 Date Founded: 2009
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Pharmaceuticals

checked-icon Does something look wrong? Fix it. | View contact records from INNOVATIVE CELLULAR THERAPEUTICS

Innovative Cellular Therapeutics Org Chart and Mapping

Employees

Rob Dallimore

Senior Vice President, Quality and Compliance

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Innovative Cellular Therapeutics

Answer: Innovative Cellular Therapeutics's headquarters are located at 1405 Research BLVD, Rockville, Maryland, 20850, United States

Answer: Innovative Cellular Therapeutics's official website is https://ictbio.com

Answer: Innovative Cellular Therapeutics's revenue is $1 Million to $5 Million

Answer: Innovative Cellular Therapeutics has 51-200 employees

Answer: Innovative Cellular Therapeutics is in Pharmaceuticals

Answer: Innovative Cellular Therapeutics contact info: Phone number: Website: https://ictbio.com

Answer: Innovative Cellular Therapeutics (ICT) is a clinical-stage, VC-backed cell therapy company based in Rockville, MD. ICT has established a broad portfolio of CAR-T products to treat cancer patients. Some highlights of the company are provided below: Leading clinical data in solid tumor CAR-T Colorectal cancer: 3rd line treatment, ~50% PR/PMR (8/16) in dose escalation trial Activity in additional solid tumor indication including thyroid and pancreas Significant market opportunity in colorectal cancer and other solid tumor cancers Lead program in colorectal cancer: Estimated 53,2001 deaths (#2 cancer death) in the U.S. in 2020 Platform technology for solid tumors, which comprise 91% of new cancer cases Strong global IP protection CoupledCAR, ArmoredCAR, and other ICT technologies protected by ~200 patents/patent applications globally, including for U.S., Europe, China and Japan

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access